The unique immune signature observed in craniopharyngiomas, characterized by an increase in epithelial–mesenchymal transition, CTLA-4, and PD-1 expression, suggests the potential for targeting these immune checkpoints. This evidence concerns the gene CTLA4 and craniopharyngioma.